Clinical considerations in study designs that use cotinine as a biomarker.
about
Cotinine: Beyond that Expected, More than a Biomarker of Tobacco Consumption.Methods for quantification of exposure to cigarette smoking and environmental tobacco smoke: focus on developmental toxicologySociodemographic characteristics and diabetes predict invalid self-reported non-smoking in a population-based study of U.S. adultsObesity and cardio-metabolic risk factors in urban adults of Benin: relationship with socio-economic status, urbanisation, and lifestyle patterns.Tobacco use induces anti-apoptotic, proliferative patterns of gene expression in circulating leukocytes of Caucasian males.Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addictionUrinary excretion of the acrylonitrile metabolite 2-cyanoethylmercapturic acid is correlated with a variety of biomarkers of tobacco smoke exposure and consumption.Family hardships and serum cotinine in children with asthma.Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction.Smoking relapse and weight gain prevention program for postmenopausal weight-concerned women: A pilot study.The use of salivary biomarkers in occupational and environmental medicine.Measuring nicotine intake among highly-dependent adolescent smokers: comparability of saliva and plasma cotinine concentrations.Evaluation of Serum Cotinine Cut-Off to Distinguish Smokers From Nonsmokers in the Korean PopulationLow-level prenatal exposure to nicotine and infant neurobehaviorEffects of Acute Vaporized Nicotine in Non-Tobacco Users at Rest and during Exercise.Blood cadmium and depressive symptoms: Confounded by cigarette smoking.Comparison of the Fagerström Test for Cigarette Dependence and the Heaviness of Smoking Index in the Second and Third Trimester of Pregnancy.Long-term follow-up of psilocybin-facilitated smoking cessation.Estimation of urinary cotinine cut-off points distinguishing non-smokers, passive and active smokers.Comparison of urinary and plasma cotinine levels during the three trimesters of pregnancy.Biomarker evaluation of Greek adolescents' exposure to secondhand smoke.Estimation of cutoff values of cotinine in urine and saliva for pregnant women in Poland.Cotinine and N-(2-hydroxyethyl)valine as markers of passive exposure to tobacco smoke in children.Examining the Validity of Self-reported Primary and Secondary Exposure to Cigarette Smoke in Adolescent Girls: The Utility of Salivary Cotinine as a Biomarker.Saliva cotinine and exhaled carbon monoxide levels in natural environment waterpipe smokers.Effect of smoking cessation for 1 year on periodontal biomarkers in gingival crevicular fluid.Mass spectrometric fragmentation and photocatalytic transformation of nicotine and cotinine.The prevalence of and factors associated with urinary cotinine-verified smoking in Korean adults: The 2008-2011 Korea National Health and Nutrition Examination Survey.Fruit and Vegetable Consumption and MortalityAn international review of tobacco smoking research in the nursing profession, 1976-2006
P2860
Q21129280-60B0F4CB-19DD-4C94-844E-AB2D2A4630F9Q24630283-BBCA9C98-D16B-4CEE-99EB-E83193661A5BQ33277968-6BCA6E6E-B387-4FA9-AD78-3B814274F7B6Q33322403-E57E6229-F0C5-45E9-A457-2B9C81A462E5Q33361063-1C7D7AD0-6A13-45E1-89C5-14861C8440A1Q34438146-F70D2929-3CD3-4C29-8F45-0E66EFE502FEQ34517983-4236A6BD-DDD4-4324-A5BF-AB85AA172CAFQ35014721-DF8CECD4-6B25-4460-B8C3-53156086C71BQ35126018-6AD3344B-7D5B-4D62-AE6B-F8B6752D9F22Q35863926-0A35ED77-F1AF-482C-ADD0-5F6248F9005DQ36166486-BBE2B2A4-61C9-41C3-8797-DB5D29CB4BE2Q36607160-151C0BBA-B313-49BD-8593-B64C1A402AA7Q37084133-1D1B6FAD-4892-4EE5-9D93-A7140A941402Q37387664-564B90D6-F756-487C-BFE0-6DAC53858455Q37500062-134F0A73-282D-42BB-B208-3DBD1107D158Q38678717-47422276-1791-4C8A-9CB5-26E6BBECB1C4Q39326865-07CDA422-7083-4823-BA68-16D0006558A0Q39577435-BDD8C670-9099-4567-B108-2BB80121F254Q39808918-2DC2BC42-45AF-43B2-9BE5-71F3BD05FBC4Q42164580-83980C80-A031-44E0-8202-D923339A0772Q43235404-48C9046A-654A-4F53-A8F9-F76DC2C03717Q43537344-897C1AF4-F046-4DC9-967B-953463F04F7CQ44803024-545CE120-CD85-463D-B289-1B45519C1840Q50067773-9663F233-F78C-4258-A4D2-8A30BBF69037Q50961456-8FB35964-DF43-47FD-B208-EC8D2F48BE7AQ51721933-8A9CAD1F-CFB7-4237-B22E-DA08C4A46280Q51780382-09376E19-D97A-48C7-885F-5561C812A35EQ55263299-EE560700-769B-476A-9052-F25338672398Q57054060-965DF1FD-C9E1-4F3D-95D1-9A30C6DB7856Q58038604-7A7C5976-A6EC-46B4-AF48-AE0E0A94BED7
P2860
Clinical considerations in study designs that use cotinine as a biomarker.
description
2003 nî lūn-bûn
@nan
2003 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Clinical considerations in study designs that use cotinine as a biomarker.
@ast
Clinical considerations in study designs that use cotinine as a biomarker.
@en
type
label
Clinical considerations in study designs that use cotinine as a biomarker.
@ast
Clinical considerations in study designs that use cotinine as a biomarker.
@en
prefLabel
Clinical considerations in study designs that use cotinine as a biomarker.
@ast
Clinical considerations in study designs that use cotinine as a biomarker.
@en
P2860
P1433
P1476
Clinical considerations in study designs that use cotinine as a biomarker.
@en
P2093
Beatrice A Kallungal
Steven L Bramer
P2860
P304
P356
10.1080/13547500310012545
P577
2003-05-01T00:00:00Z